Nrf2 Upregulates ATP Binding Cassette Transporter Expression and Activity at the Blood-Brain and Blood-Spinal Cord Barriers
Open Access
- 18 June 2014
- journal article
- Published by Society for Neuroscience in Journal of Neuroscience
- Vol. 34 (25), 8585-8593
- https://doi.org/10.1523/jneurosci.2935-13.2014
Abstract
Activation of nuclear factor E2-related factor-2 (Nrf2), a sensor of oxidative stress, is neuroprotective in animal models of cerebral ischemia, traumatic brain injury, subarachnoid hemorrhage, and spinal cord injury. We show here that Nrf2 activation with sulforaphane (SFN) in vivo or in vitro increases expression and transport activity of three ATP-driven drug efflux pumps at the blood–brain barrier [P-glycoprotein, ATP binding cassette b1 (Abcb1); multidrug resistance-associated protein-2 (Mrp2), Abcc2; and breast cancer resistance protein (Bcrp), Abcg2]. Dosing rats with SFN increased protein expression of all three transporters in brain capillaries and decreased by 50% brain accumulation of the P-glycoprotein substrate verapamil. Exposing rat or mouse brain capillaries to SFN increased P-glycoprotein, Bcrp, and Mrp2 transport activity and protein expression; SFN increased P-glycoprotein activity in mouse spinal cord capillaries. Inhibiting transcription or translation abolished upregulation of P-glycoprotein activity. No such effects were seen in brain capillaries from Nrf2-null mice, indicating Nrf2 dependence. Nrf2 signaled indirectly to increase transporter activity/expression. The p53 inhibitor pifithrin abolished the SFN-induced increase in transporter activity/expression, and the p53-activator nutlin-3 increased P-glycoprotein activity. SFN did not alter P-glycoprotein transport activity in brain and spinal cord capillaries from p53-null mice. Inhibitors of p38 MAPK and nuclear factor κB (NF-κB) blocked the effects of SFN and nutlin-3 on P-glycoprotein activity. These results implicate Nrf2, p53, and NF-κB in the upregulation of P-glycoprotein, Bcrp, and Mrp2 at blood–CNS barriers. They imply that the barriers are tightened selectively (efflux transporter upregulation) by oxidative stress, providing increased neuroprotection, but also reduced penetration of many therapeutic drugs.Keywords
This publication has 42 references indexed in Scilit:
- Targeting blood-brain barrier sphingolipid signaling reduces basal P-glycoprotein activity and improves drug delivery to the brainProceedings of the National Academy of Sciences of the United States of America, 2012
- Activation of the Nuclear Factor E2-Related Factor 2/Antioxidant Response Element Pathway Is Neuroprotective after Spinal Cord InjuryJournal of Neurotrauma, 2012
- Targeting the Nrf2–Keap1 antioxidant defence pathway for neurovascular protection in strokeThe Journal of Physiology, 2011
- When NRF2 Talks, Who's Listening?Antioxidants and Redox Signaling, 2010
- Aryl hydrocarbon receptor‐mediated up‐regulation of ATP‐driven xenobiotic efflux transporters at the blood‐brain barrierThe FASEB Journal, 2010
- Constitutive Androstane Receptor-Mediated Up-Regulation of ATP-Driven Xenobiotic Efflux Transporters at the Blood-Brain BarrierMolecular Pharmacology, 2010
- Regulation of P-glycoprotein and other ABC drug transporters at the blood–brain barrierTrends in Pharmacological Sciences, 2010
- Rapid, Reversible Modulation of Blood–Brain BarrierP-Glycoprotein Transport Activity by Vascular Endothelial Growth FactorJournal of Neuroscience, 2010
- Sulforaphane improves cognitive function administered following traumatic brain injuryNeuroscience Letters, 2009
- Interaction of diuron and related substituted phenylureas with the Ah receptor pathwayJournal of Biochemical and Molecular Toxicology, 2006